Prof Nicolas Girard speaks to ecancer about the updated results from the PALOMA-2 study.

He reviews long-term results for the subcutaneous formulation of amivantamab combined with lazertinib as first-line treatment for patients with EGFR-mutated advanced non-small cell lung cancer.

The study demonstrated high response rates and durable clinical benefit, with prolonged progression-free survival and sustained responses in nearly half of patients.

The safety profile remained consistent with prior data, with no new safety signals observed over extended follow-up.

Importantly, the subcutaneous formulation offers a more convenient and patient-friendly approach, significantly reducing administration time and infusion-related reactions compared with intravenous delivery.

These findings support subcutaneous amivantamab plus lazertinib as an effective and improved treatment option in this setting.